Trial · NCT04276090
Trial comparisons13
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
1 to 13 of 13
Download this page as JSON| Comparison | Source |
|---|---|
| Colorectal Liver Metastases vs Intrahepatic Cholangiocarcinoma: Percent Completion of 1st Cycle of Hepatic Artery Chemotherapy | Trial comparisons |
| Colorectal Liver Metastases vs Intrahepatic Cholangiocarcinoma: Number of Interventions (Phone Calls) to Assure Patients Attend Followup Appointments. | Trial comparisons |
| Colorectal Liver Metastases vs Intrahepatic Cholangiocarcinoma: 30-day Postoperative Serious Adverse Events Related to Pump Implantation | Trial comparisons |
| Colorectal Liver Metastases vs Intrahepatic Cholangiocarcinoma: Percent of Screened Patients That Are Declined Due to High Risk of Failure as Determined by the Psychosocial Assessment Tool. | Trial comparisons |
| Colorectal Liver Metastases vs Intrahepatic Cholangiocarcinoma: Percent of Patients Who Are Downstaged and Undergo Surgery | Trial comparisons |
| Colorectal Liver Metastases vs Intrahepatic Cholangiocarcinoma: 30-day Catheter Malfunction Due to Inability to Access Pump | Trial comparisons |
| Colorectal Liver Metastases vs Intrahepatic Cholangiocarcinoma: Percent of Patients Who Remain on Hepatic Artery Infusion Pump Chemotherapy at 3 Months. | Trial comparisons |
| Colorectal Liver Metastases vs Intrahepatic Cholangiocarcinoma: Percent of Patients That Require Secondary Intervention in Order to Obtain Primary Pump Function. | Trial comparisons |
| Colorectal Liver Metastases vs Intrahepatic Cholangiocarcinoma: deaths from any cause | Trial comparisons |
| Colorectal Liver Metastases vs Intrahepatic Cholangiocarcinoma: 30-day Catheter Malfunction Due to Tubing Disconnect | Trial comparisons |
| Colorectal Liver Metastases vs Intrahepatic Cholangiocarcinoma: Percent of Patients Who Remain on Hepatic Artery Infusion Pump Chemotherapy at 6 Months. | Trial comparisons |
| Colorectal Liver Metastases vs Intrahepatic Cholangiocarcinoma: Percent Pump Loss Due to Inability to Attend Scheduled Followup Appointments. | Trial comparisons |
| Colorectal Liver Metastases vs Intrahepatic Cholangiocarcinoma: serious adverse events | Trial comparisons |
trials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04276090/comparisons